{
  "source": "PA-Med-Nec-Sucraid.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2179-8\nProgram Prior Authorization/Medical Necessity\nMedication Sucraid (sacrosidase) oral solution\nP&T Approval Date 12/2019, 1/2020, 1/2021, 1/2022, 1/2023, 1/2024, 4/2024, 1/2025\nEffective Date 4/1/2025\n1. Background:\nSucraid (sacrosidase) is an oral enzyme replacement therapy indicated for the treatment of sucrase\ndeficiency, which is part of congenital sucrase-isomaltase deficiency (CSID). The effects of\nSucraid have not been evaluated in patients with secondary (acquired) sucrase deficiency.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Sucraid will be approved based on all of the following criteria:\na. Submission of medical records documenting a diagnosis of congenital sucrase-\nisomaltase deficiency (CSID)\n-AND-\nb. Submission of medical records documenting diagnosis has been confirmed by one of\nthe following:\n(1) Endoscopic biopsy of the small bowel indicating all of the following:\n(a) Normal small bowel morphology\n-AND-\n(b) Absent or markedly reduced sucrase activity\n-AND-\n(c) Isomaltase activity varying from 0 to full activity\n-AND-\n(d) Reduced maltase activity\n-AND-\n(e) One of the following:\ni. Normal lactase activity\n© 2025 UnitedHealthcare Services Inc.\n1\n-OR-\nii. Both of the following:\n• Reduced lactase\n• Sucrase:lactase ratio of < 1.0\n-OR-\n(2) Molecular genetic testing of the sucrase-isomaltase (SI) gene indicating a\npathogenic isomaltase gene variant\n-OR-\n(3) Carbon-13 sucrose breath test (13C SBT) indicating a cumulative [13C] CO\n2\nexhalation over 90 minutes below 10th percentile (i.e., < 3.9% for men and < 5.2%\nfor women)\n-AND-\nc. Prescribed by or in consultation with a gastroenterologist or rare disease specialist\n-AND-\nd. Will be used with a sucrose-free, low starch diet\nAuthorization will be issued for 3 months.\nB. Reauthorization\n1. Sucraid will be approved based on all of the following criterion:\na. Documentation of positive clinical response Sucraid therapy [e.g., ",
    "uthorization will be issued for 3 months.\nB. Reauthorization\n1. Sucraid will be approved based on all of the following criterion:\na. Documentation of positive clinical response Sucraid therapy [e.g., reduced symptoms\n(e.g., abdominal pain, bloating, gas, vomiting), reduced number of stools per day,\nreduced number of symptomatic days]\n-AND-\nb. Prescribed by or in consultation with a gastroenterologist or rare disease specialist\n-AND-\nc. Will be used with a sucrose-free, low starch diet\nAuthorization will be issued for 12 months.\n© 2025 UnitedHealthcare Services Inc.\n2\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Prior Authorization/Notification may be in place.\n4. References:\n1. Sucraid [package insert]. Vero Beach, FL: QOL Medical, LLC; August 2024.\n2. Danialifar TF, Chumpitazi BP, Mehta DI, Di Lorenzo C. Genetic and acquired sucrase-isomaltase\ndeficiency: A clinical review. J Pediatr Gastroenterol Nutr. 2024;78(4):774-782.\n3. Congenital sucrase-isomaltase deficiency. U.S. Nation Library of Medicine. October 2019.\n4. Puntis JW, Zamvar V. Congenital sucrase-isomaltase deficiency: diagnostic challenges and\nresponse to enzyme replacement therapy. Arch Dis Child. September 2015.\n5. Treem WR. Clinical aspects and treatment of congenital sucrase-isomaltase deficiency. J Ped\nGastro Nutr. 55 (Sup 2 Nov): S7-S13. November 2012.\n6. Treem WR, McAdams L, Stanford L, Kastoff G, Justinich C, Hyams J. Sacrosidase therapy for\ncongenital sucrase-isomaltase deficiency. J Pediatr Gastroenterol Nutr. 1999 Feb;28(2",
    "7-S13. November 2012.\n6. Treem WR, McAdams L, Stanford L, Kastoff G, Justinich C, Hyams J. Sacrosidase therapy for\ncongenital sucrase-isomaltase deficiency. J Pediatr Gastroenterol Nutr. 1999 Feb;28(2):137-42.\ndoi: 10.1097/00005176-199902000-00008. PMID: 9932843.\n7. Robayo-Torres CC, Opekun AR, Quezada-Calvillo R, Villa X, Smith EO, Navarrete M, Baker\nSS, Nichols BL. 13C-breath tests for sucrose digestion in congenital sucrase isomaltase-deficient\nand sacrosidase-supplemented patients. J Pediatr Gastroenterol Nutr. 2009 Apr;48(4):412-8. doi:\n10.1097/mpg.0b013e318180cd09. PMID: 19330928; PMCID: PMC3955999.\nProgram Prior Authorization/Medical Necessity – Sucraid\nChange Control\n12/2019 New program\n1/2020 Administrative; criteria clarification\n1/2021 Annual review. Updated references.\n1/2022 Annual review. Updated coverage criteria with current testing\nguidelines.\n1/2023 Annual review with no changes to coverage criteria. Updated\nreferences.\n1/2024 Annual review. Updated confirmation of diagnosis requirements for\ninitial authorization. Simplified reauthorization criteria. Updated\nreferences.\n4/2024 Added carbon-13 sucrose breath test as an acceptable confirmatory\ndiagnostic test. Updated references.\n© 2025 UnitedHealthcare Services Inc.\n3\n1/2025 Added requirement for submission of medical records documenting\ndiagnosis and confirmation of diagnosis. Updated background\nreferences.\n© 2025 UnitedHealthcare Services Inc.\n4"
  ]
}